Advanced Search >

Risk Minimisation Materials

Valsartan/HCTZ - HCP Letter - Hydrochlorothiazide and the risk of non-melanoma skin cancer

The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer

For Healthcare Professionals

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue